Zoledronic Acid Disodium Salt Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bisphosphonate compounds, such as zoledronic acid, have low oral bioavailability, limiting their effectiveness in treating bone-related and cancer-related conditions, and existing dosage forms do not adequately enhance bioavailability for pain relief in conditions like osteoporosis, Paget's disease, and complex regional pain syndrome.
Innovation Solution
Administering zoledronic acid in the disodium salt form, which has improved bioavailability compared to the diacid form, allowing for reduced molar amounts while maintaining effective plasma concentrations, and providing pain relief for conditions like osteoporosis, Paget's disease, and complex regional pain syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If zoledronic acid is administered in the diacid form, then the dosage form is stable and easy to manufacture, but the oral bioavailability is low
Solution Approach 1:
The patent changes the chemical form of zoledronic acid from diacid to disodium salt, which fundamentally alters the bioavailability parameter while maintaining manufacturing feasibility through standard pharmaceutical salt formation processes
Solution Approach 2:
Sodium ions act as an intermediary that facilitates the absorption and bioavailability of zoledronic acid in the oral dosage form, enabling improved drug delivery without compromising formulation stability
2Reliability
If higher doses of zoledronic acid are administered to improve bioavailability, then pain relief effectiveness increases, but the risk of adverse effects increases
Solution Approach 1:
By changing the salt form to disodium salt, the patent achieves improved bioavailability at lower effective doses, thereby reducing the dose-related adverse effects while maintaining therapeutic effectiveness for pain relief
Solution Approach 2:
The patent employs a more efficient molecular form (disodium salt) that provides better bioavailability, allowing the use of lower effective doses that minimize adverse effects while maintaining therapeutic benefit
Data Source
AI summary
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.